Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid Carcinoma

Kim, Sungeun; Chung, June Key; Min, Hong‐Shick; Kang, Joo Hyun; Park, Do Joon; Jeong, Jae Min; Lee, Dong Hoon; Park, Sung Hwae; Cho, Bo Youn; Lee, Sinae; Lee, Myung Chul

doi:10.1007/s13139-013-0249-x

Cited by 36 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a controversy regarding the correlation of BRAFV600E, GLUT1, and tumor differentiation genes according to several previous reports (16)(17)(18). Our results are consistent with other results of higher GLUT1 in less differentiated thyroid cancer (16) and negative correlation between BRAFV600E mutation and tumor differentiation genes in PTC (17,18). The results of TDS positively correlated with glycolysis and negatively correlated with GLUT were particularly found in PTC without BRAFV600E mutation.…”

Section: Discussionsupporting

confidence: 88%

Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer

Suh

Choi

Paeng

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The principle of loss of iodine uptake and increased glucose metabolism according to dedifferentiation of thyroid cancer is clinically assessed by imaging. Though these biological properties are widely applied to appropriate iodine therapy, the understanding of the genomic background of this principle is still lacking. We investigated the association between glucose metabolism and differentiation in advanced thyroid cancer as well as papillary thyroid cancer (PTC). Methods: We used RNA sequencing of 505 patients with PTC obtained from the Cancer Genome Archives and microarray data of poorly-differentiated and anaplastic thyroid cancer (PDTC/ATC). The signatures of GLUT and glycolysis were estimated to assess glucose metabolic profiles. The glucose metabolic profiles were associated with tumor differentiation score (TDS) and BRAFV600E mutation status. In addition, survival analysis of glucose metabolic profiles was performed for predicting recurrence-free survival. Results: In PTC, the glycolysis signature was positively correlated with TDS, while the GLUT signature was inversely correlated with TDS. These correlations were significantly stronger in the BRAFV600E negative group than the positive group. Meanwhile, both GLUT and glycolysis signatures were negatively correlated with TDS in advanced thyroid cancer. The high glycolysis signature was significantly associated with poor prognosis in PTC in spite of high TDS. The glucose metabolic profiles are intricately associated with tumor differentiation in PTC and PDTC/ATC. Conclusions: As glycolysis was an independent prognostic marker, we suggest that the glucose metabolism features of thyroid cancer could be another biological progression marker different from differentiation and provide clinical implications for risk stratification.

show abstract

Section: Discussionsupporting

confidence: 88%

Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer

Suh

Choi

Paeng

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although there is a possibility of false-negative or -positive results for BRAF mutation analysis, these patients suggest that factors other than tumor size or BRAF mutation status are associated with 18 F-FDG avidity, such as the differentiation status, RAS or RET/PTC oncogene, etc. [11,12]. The clinical relevance of this study might be that the results could offer a suggestion regarding the usage of 18 F-FDG PET in PTC patients.…”

Section: Discussionmentioning

confidence: 72%

“…A recent report also showed that relatively well differentiated PTCs have high expression of iodine metabolism-related genes, such as sodium/iodide symporter and pendrin genes, whereas less differentiated PTCs have high expression of the GLUT-1 transporter gene [12]. However, this 'flip-flop' phenomenon, which refers to the inverse correlation between iodine uptake and 18 F-FDG uptake [11], can also be explained by the BRAF mutation.…”

Section: Introductionmentioning

confidence: 99%

Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma

Lee

Han

Lee

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence 18 F-fluoro-2-deoxyglucose ( 18 F-FDG) avidity. Methods We retrospectively reviewed 55 patients who underwent BRAF analysis from biopsy-confirmed PTC and 18 F-FDG positron emission tomography/computed tomography within 6 months before undergoing thyroid surgery from September 2008 to August 2014. Tumors were considered to be 18 F-FDG avid if the uptake was greater than that of the liver. 18 F-FDG uptake of PTCs was also analyzed semiquantitatively using SUV max . The association between 18 F-FDG avidity and clinicopathologic variables (age, tumor size, perithyroidal extension, cervical lymph node status, and BRAF mutation status) was investigated. Results Twenty-nine (52.7 %) of 55 patients had 18 F-FDGavid PTCs. PTCs with the BRAF mutation showed higher 18 F-FDG avidity (24/38, 63.2 %) than those without (5/17, 29.4 %). The BRAF mutation (p=0.025) and tumor size (p= 0.003) were significantly associated with 18 F-FDG avidity in univariate analysis, and the BRAF mutation status remained significant after adjusting for tumor size in multivariate analysis (p=0.015). In the subgroup of tumor size≥1 cm, the BRAF mutation was the only factor significantly associated with 18 F-FDG avidity (p=0.021). The mean SUV max of PTCs with the BRAF mutation was significantly higher than that of those without (4.89±6.12 vs. 1.96±1.10, p=0.039). Conclusions The BRAF mutation must be one of the most important factors influencing 18 F-FDG avidity in PTCs, especially in those with a tumor size≥1 cm.

show abstract

“…При более низкой степени дифференцировки клеток рака щитовидной железы экспрессия NIS снижается, при этом увеличивается продукция GLUT-1 и гексокиназы, что обеспечивает накопление 18 F-ФДГ [13]. Различный уровень экспрессии в клетках опухоли GLUT-1 и NIS определяет разную степень накопления радиойода и 18 F-ФДГ [18,19]. Сопоставление результатов диагностических методов особенно важно при наличии признаков рефрактерности к радиойоду и высоком риске прогрессирования опухоли.…”

Section: результатыunclassified

<sup>18</sup>F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer

Гелиашвили

Важенин

Березовская

et al. 2020

Opuholi golovy i šei

View full text Add to dashboard Cite

The study objective was to investigate the role of 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography combined with computed tomography (PET-CT) as an indirect determination of the differentiation status of metastases and for the prediction of radioactive iodine (RAI) therapy response in patients with metastatic differentiated thyroid cancer.Materials and methods. The 40 metastatic differentiated thyroid cancer patients were enrolled in the study that underwent both post-therapeutic radioiodine scan and PET-CT at the same period.Results. The study found that 12 (30 %) patients responded to RAI therapy. The remaining 28 (70 %) patients not responded to RAI therapy showed stabilization or progression. The accumulation of radioiodine by metastases positively correlated with the total response rate, while the 18 F-FDG avidity is negative. Significant direct correlation with response rate was observed in the group with only radioiodine uptake. However, this correlation was not observed in the patients with both tracers uptake. The patients with 18 F-FDG-positive metastases showed poor response to RAI therapy, regardless of the degree of radioiodine uptake.Conclusion. The 18 F-FDG uptake by metastases is a predictor of a poor response to RAI therapy, even in the presence of RAI uptake. The use of 18 F-FDG PET-CT in patients with metastatic differentiated thyroid cancer can be recommended at the beginning of RAI therapy to clarify the prognosis and provide a personalized approach to the treatment and observation of the most difficult category of patients.

show abstract

Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid Carcinoma

Cited by 36 publications

References 28 publications

Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer

Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer

Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma

<sup>18</sup>F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer

Contact Info

Product

Resources

About